Evan began his career at the Innovation Institute in January of 2014. Prior to being named Interim Director, he lead the Institute’s initiatives to commercialize University innovations. Before joining Pitt, Evan was President/CEO of SironRX Therapeutics, a biotechnology company developing novel drug therapies. Prior to this, Evan worked in Bayer Healthcare’s medical device division as General Manager of Pittsburgh Interventional. While here he also served as Executive Director, Corporate Development overseeing company strategy and M&A. Before this, Evan was Senior Manager, Business Development at the biotechnology company Athersys where he was a leader in creating partnerships with global pharmaceutical companies such as Pfizer, Bristol-Myers Squibb and Johnson & Johnson among others. Over his career, Evan has been involved with corporate fundraising rounds of approximately $100 million, as well as company and product acquisitions totaling nearly $600 million. Evan holds a Ph.D. in Human Genetics from the University of Pittsburgh, an MBA with a concentration in Entrepreneurship from Case Western Reserve University and a B.S. in Biology from the University of Miami.